As new medications enter the market, we’ve observed a troubling new trend: an influx of clinically superfluous brand drugs that carry hefty price tags but offer little to no added clinical value.
Recently, manufacturers have launched new brand-name prescription wound dressings that include similar combinations of ingredients as OTC and lower-cost generic products yet are priced far higher than the alternatives — up to 125 times more.
This report shines a spotlight on:
- What’s driving the increased need for wound care.
- The potential effects of high-cost prescription wound dressings on patients and plan sponsors.
- How Optum Rx helps improve the quality of care while lowering costs.
Related healthcare insights
Article
Discover how a digital-first DME strategy can enhance efficiency and transparency for health plans, clinicians and members.
Podcast
Join host Adia Morris for inspiring chats with clinicians on care, culture and how Optum supports their journey every step of the way.
Article
See the critical products our clients use to manage drug spend and improve outcomes.